Trials of implant for chronic lower back pain begin in the UK

Clinical trials of ReActiv8, a new device for people with chronic low back pain are now taking place in the UK. The Medicines and Healthcare Products Regulatory Agency (MHRA) and the Central Ethics Committee have agreed to expand the clinical trial of ReActiv8, an implantable neurostimulation device and enrollment of participants is now taking place.
“We are pleased to expand the clinical trial to the UK sites as planned,” comments Peter Crosby, chief executive officer from Mainstay (the company behind the device). “This continues our steady progress towards regulatory approval and commercialization of ReActiv8. When available, ReActiv8 has the potential to change the lives of the millions of people who suffer from chronic low back pain.”
The clinical trial of ReActiv8 started in March 2014, and several sites in Australia and Belgium continue to actively enrol volunteers. The purpose of the clinical trial is to investigate ReActiv8 as a treatment for adults with debilitating Chronic Low Back Pain who have few other treatment options.
More details of the clinical trial, including identification of active investigation sites, can be found here.